An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis

Journal of the American Academy of Dermatology

Volumn 53, Issue 1, 2005, Pages 73-75

  Gribetz, Carin H ^a   Blum, Robin ^a   Brady, Christopher ^a   Cohen, Steven ^a   Lebwohl, Mark ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT;

ADULT; ARTICLE; BRONCHITIS; CELLULITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INJECTION PAIN; LIPODERMATOSCLEROSIS; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION;

CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RECOMBINANT FUSION PROTEINS; TIME FACTORS;

EID: 20444492267     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2005.03.053     Document Type: Article

References (4)

1. C.N. Ellis, G.G. Krueger for the Alefacept Clinical Study Group Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes N Engl J Med 345 2001 248 255
2. G.G. Krueger, K.A. Papp, D.B. Stough, K.H. Loven, W.P. Gulliver, C.N. Ellis for the Alefacept Clinical Study Group A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis J Am Acad Dermatol 47 2002 821 833
3. M. Lebwohl, E. Christophers, R. Langley, J.P. Ortonne, J. Roberts, C.E.M. Griffiths for the Alefacept Clinical Study Group An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis Arch Dermatol 139 2003 719 727
4. K.B. Gordon, and R.G. Langley Remittive effects of intramuscular alefacept in psoriasis J Drugs Dermatol 2 2003 624 628